William K. Heiden
William K. Heiden's purchase track record
William K. Heiden has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/19/2025 | MGNX | $151K | +3.4% | +14.1% | +6.7% |
| 11/10/2023 | ATRA | $25K | +256.5% | +130.4% | +18.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
MGNX mentioned in medical stock sector review. MacroGenics was included in a recent Yahoo Finance article examining the performance of medical stocks this year. The stock is currently trading near its 52-week low, with technical indicators showing weakness near key support levels. This context highlights the broader sector trends affecting the company's valuation.
Transaction History
| ATRA | ▲ Buy | Grant | 12,000 | $0 | 6/9/2026 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 3,750 | — | 5/18/2026 | View on chart |
| MGNX | ▲ Buy | Open Market | 49,500 | $74K | 8/20/2025 | View on chart |
| MGNX | ▲ Buy | Open Market | 50,500 | $77K | 8/19/2025 | View on chart |
| ATRA | ▲ Buy | Grant | 7,828 | $0 | 6/10/2025 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 6,500 | — | 5/20/2025 | View on chart |
| MGNX | ▲ Buy | Option Exercise | 4,500 | $0 | 5/20/2024 | View on chart |
| ATRA | ▲ Buy | Grant | 150,000 | $0 | 3/31/2024 | View on chart |
| ATRA | ▲ Buy | Open Market | 100,000 | $25K | 11/10/2023 | View on chart |
| ATRA | ▲ Buy | Grant | 57,000 | $0 | 5/31/2023 | View on chart |
| ATRA | ▲ Buy | Grant | 20,500 | $0 | 6/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA
Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA. Atara Biotherapeutics and its partner Pierre Fabre have filed a new biologics license application for the Tabelecleucel therapy with the U.S. FDA. The resubmission follows the earlier filing and reflects the companies' effort to move the product toward approval. The stock is currently near a long‑standing support level, which may be watched as the regulatory process continues.